{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:42Z","timestamp":1792096782852,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.schres.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T19:02:26Z","timestamp":1654887746000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study"],"prefix":"10.1016","volume":"246","author":[{"given":"Sara","family":"Galiano Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Ortiz Garc\u00eda de la Foz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Arias-Loste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Iruzubieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"G\u00f3mez-Revuelta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Juncal-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2022.06.001_bb0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10654-020-00627-2","article-title":"Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population","volume":"35","author":"Alferink","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2020.02.028","article-title":"Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH","volume":"73","author":"Ampuero","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.schres.2022.06.001_bb0015","series-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.schres.2022.06.001_bb0020","series-title":"Scale for the Assessment of Positive Symptoms (SAPS)","volume":"Vol. 17","author":"Andreasen","year":"1984"},{"key":"10.1016\/j.schres.2022.06.001_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2022.06.001_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.schres.2022.06.001_bb0035","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","article-title":"High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study","volume":"16","author":"Caballer\u00eda","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.24356","article-title":"Fatty liver index and mortality: the Cremona study in the 15th year of follow-up","volume":"54","author":"Calori","year":"2011","journal-title":"Hepatology"},{"issue":"2\u20133","key":"10.1016\/j.schres.2022.06.001_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.schres.2016.01.010","article-title":"Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis","volume":"170","author":"Carney","year":"2016","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2022.06.001_bb0050","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.schres.2022.06.001_bb0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.06.001_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2011.03.031","article-title":"Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs)","volume":"130","author":"Ellingrod","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.06.001_bb0065","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/NDT.S50006","article-title":"Etiology of cardiovascular disease in patients with schizophrenia: current perspectives","volume":"11","author":"Emul","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2022.06.001_bb0070","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version","author":"First","year":"2002"},{"issue":"7","key":"10.1016\/j.schres.2022.06.001_bb0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.schres.2022.06.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study)","volume":"10","author":"Karajamaki","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.schres.2022.06.001_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2022.06.001_bb0095","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","article-title":"External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study","volume":"11","author":"Koehler","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.06.001_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.schres.2012.02.007","article-title":"Reduced arterial compliance in patients with psychiatric diagnoses","volume":"137","author":"Koola","year":"2012","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2022.06.001_bb0105","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s10620-019-05986-9","article-title":"Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany","volume":"65","author":"Labenz","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"10","key":"10.1016\/j.schres.2022.06.001_bb0110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2022.06.001_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12072-020-10132-z","article-title":"Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study","volume":"15","author":"Ma","year":"2021","journal-title":"Hepatol. Int."},{"issue":"8","key":"10.1016\/j.schres.2022.06.001_bb0125","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc16-0091","article-title":"Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring","volume":"39","author":"Mantovani","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.schres.2022.06.001_bb0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cld.806","article-title":"Epidemiology of alcohol use and alcoholic liver disease","volume":"13","author":"Mellinger","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.schres.2022.06.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796020001146","article-title":"Excess mortality in patients with schizophrenia spectrum disorders in malaga (Spain): a cohort study","volume":"30","author":"Moreno-Kustner","year":"2021","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"23\u201324","key":"10.1016\/j.schres.2022.06.001_bb0140","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00213-016-4422-7","article-title":"Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study","volume":"233","author":"Morlan-Coarasa","year":"2016","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.06.001_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2013.02.025","article-title":"Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades\u2013a danish nationwide study from 1980 to 2010","volume":"146","author":"Nielsen","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2022.06.001_bb0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the clinical programme on early phases of psychosis","volume":"2","author":"Pelayo-Teran","year":"2008","journal-title":"Early Interv. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2022.06.001_bb0170","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J. Hepatol."},{"issue":"24","key":"10.1016\/j.schres.2022.06.001_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249362","article-title":"Understanding mechanisms underlying non-alcoholic fatty liver disease (NAFLD) in mental illness: risperidone and olanzapine alter the hepatic proteomic signature in mice","volume":"21","author":"Rostama","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.schres.2022.06.001_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/tgh.2019.10.02","article-title":"Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis","volume":"5","author":"Sharma","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.schres.2022.06.001_bb0185","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jgh.14856","article-title":"Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study","volume":"35","author":"Sinn","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.schres.2022.06.001_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.564240","article-title":"Cardiometabolic risk in first episode psychosis patients","volume":"11","author":"Smith","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.schres.2022.06.001_bb0195","article-title":"Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)","author":"Son","year":"2021","journal-title":"Rev. Psiquiatr. Salud Ment."},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0205","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/wps.20069","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","author":"Vancampfort","year":"2013","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0210","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-017-4763-x","article-title":"Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naive patients with a first-episode of non-affective psychosis","volume":"235","author":"Vazquez-Bourgon","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2022.06.001_bb0220","doi-asserted-by":"crossref","first-page":"109677","DOI":"10.1016\/j.pnpbp.2019.109677","article-title":"Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients","volume":"95","author":"Vazquez-Bourgon","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2022.06.001_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euroneuro.2020.08.009","article-title":"A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients","volume":"39","author":"Vazquez-Bourgon","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyaa066","article-title":"Treatment discontinuation impact on long-term (10-Year) weight gain and lipid metabolism in first-episode psychosis: results from the PAFIP-10 cohort","volume":"24","author":"Vazquez-Bourgon","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2022.06.001_bb0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.schres.2022.06.001_bb0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.9758\/cpn.2020.18.1.67","article-title":"Metformin attenuates liver fat content: finding from schizophrenia patients with olanzapine-induced weight gain","volume":"18","author":"Wang","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2022.06.001_bb0245","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.schres.2022.06.001_bb0250","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.schres.2022.06.001_bb0255","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/NDT.S208061","article-title":"Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review","volume":"15","author":"Xu","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:47:12Z","timestamp":1760298432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996422002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":51,"alternative-id":["S0920996422002067"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2022.06.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}